Health Catalyst, Inc. (NASDAQ:HCAT) Sees Significant Growth in Short Interest

Health Catalyst, Inc. (NASDAQ:HCAT) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 2,840,000 shares, a growth of 8.8% from the October 15th total of 2,610,000 shares. Based on an average daily trading volume, of 473,600 shares, the days-to-cover ratio is presently 6.0 days.

Health Catalyst Stock Down 1.6 %

Shares of NASDAQ:HCAT traded down $0.12 during trading on Monday, hitting $7.53. The company’s stock had a trading volume of 524,727 shares, compared to its average volume of 562,774. The business has a 50 day moving average price of $8.16 and a two-hundred day moving average price of $7.23. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst has a fifty-two week low of $5.42 and a fifty-two week high of $11.41. The company has a market capitalization of $458.19 million, a PE ratio of -5.62 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The firm had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $76.27 million. During the same period last year, the firm posted ($0.22) earnings per share. Health Catalyst’s revenue for the quarter was up 3.5% on a year-over-year basis. As a group, research analysts expect that Health Catalyst will post -0.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on HCAT. Citigroup raised their target price on Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a report on Friday, October 4th. JPMorgan Chase & Co. lifted their price target on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Royal Bank of Canada boosted their price target on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. Finally, Stephens increased their price objective on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research report on Thursday. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.71.

Insider Activity at Health Catalyst

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total value of $40,005.12. Following the completion of the sale, the chief operating officer now directly owns 134,899 shares in the company, valued at $1,036,024.32. This represents a 3.72 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the transaction, the insider now directly owns 255,881 shares in the company, valued at approximately $1,847,460.82. The trade was a 2.85 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 34,068 shares of company stock valued at $257,555. 2.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Quest Partners LLC purchased a new stake in Health Catalyst in the third quarter valued at $34,000. Nisa Investment Advisors LLC lifted its holdings in shares of Health Catalyst by 461.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after purchasing an additional 5,232 shares during the last quarter. Quarry LP boosted its position in shares of Health Catalyst by 59.4% in the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after purchasing an additional 2,610 shares during the period. nVerses Capital LLC purchased a new position in Health Catalyst during the 3rd quarter worth approximately $59,000. Finally, Perfromance Wealth Partners LLC acquired a new position in Health Catalyst during the second quarter worth approximately $64,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.